Belgian biotech Galapagos is getting out of the CRO business, selling off its two contract units to preclinical giant Charles River Laboratories for $179 million and planning to put the proceeds into its pipeline.

…read more

Source: Galapagos ships out its CRO biz for $179M to focus on R&D


0 No comments